Vertex Pharmaceuticals Incorporated
VRTX
$387.18
-$1.76-0.45%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 842.52% | -124.60% | -114.80% | -113.83% | -114.56% |
| Total Depreciation and Amortization | -11.28% | -3.96% | 7.37% | 29.37% | 26.72% |
| Total Amortization of Deferred Charges | 113.56% | 113.56% | 113.56% | -- | -- |
| Total Other Non-Cash Items | 717.51% | 18,338.46% | 16,595.24% | -21.39% | -42.81% |
| Change in Net Operating Assets | -5.45% | -231.49% | -93.75% | -264.52% | -303.66% |
| Cash from Operations | 507.46% | -124.86% | -113.93% | -119.23% | -123.20% |
| Capital Expenditure | -46.84% | -19.10% | -48.55% | -49.63% | -24.59% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 59.52% | 55.89% | -18.05% | -87.60% | -81.02% |
| Cash from Investing | 52.55% | 50.95% | -20.00% | -84.39% | -53.63% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 81.47% | 54.32% | 25.17% | -2.31% | 38.40% |
| Issuance of Common Stock | -18.85% | -16.68% | -14.86% | -9.37% | -16.96% |
| Repurchase of Common Stock | -75.57% | -166.20% | -142.02% | -160.31% | -185.74% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -17.50% | -16.67% | 244.44% | 322.22% | 700.00% |
| Cash from Financing | -80.68% | -190.85% | -165.90% | -204.18% | -236.55% |
| Foreign Exchange rate Adjustments | 578.79% | 600.00% | -258.36% | -20.35% | -153.66% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 107.03% | -3,453.09% | -4,051.83% | -402.56% | -483.80% |